1. Home
  2. MRKR vs BESS Comparison

MRKR vs BESS Comparison

Compare MRKR & BESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$1.00

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Logo Bimergen Energy Corporation Common Stock

BESS

Bimergen Energy Corporation Common Stock

N/A

Current Price

$2.34

Market Cap

16.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MRKR
BESS
Founded
1999
1998
Country
United States
United States
Employees
N/A
3
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
16.8M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
MRKR
BESS
Price
$1.00
$2.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$7.87
★ $9.75
AVG Volume (30 Days)
★ 168.4K
98.3K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.61
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $168,880.00
Revenue This Year
$19.61
N/A
Revenue Next Year
$375.85
$206.88
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.84
$1.52
52 Week High
$2.46
$6.45

Technical Indicators

Market Signals
Indicator
MRKR
BESS
Relative Strength Index (RSI) 45.81 51.93
Support Level $0.88 $2.03
Resistance Level $1.32 $2.46
Average True Range (ATR) 0.12 0.23
MACD 0.00 0.05
Stochastic Oscillator 31.33 82.84

Price Performance

Historical Comparison
MRKR
BESS

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About BESS Bimergen Energy Corporation Common Stock

Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.

Share on Social Networks: